Improving clinical trial design for hepatocellular carcinoma treatments
Despite its place as the third leading cause of cancer deaths worldwide, there are currently no approved chemotherapeutic agents, devices or techniques to treat hepatocellular carcinoma. Importantly, there have been no phase III studies demonstrating survival benefit, nor any randomized studies of t...
Saved in:
Main Authors: | Robert G. Gish (Author), Garrett Hisatake (Author) |
---|---|
Format: | Book |
Published: |
Frontiers Media S.A.,
2011-12-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Improving clinical trial design for hepatocellular carcinoma treatments
by: Robert G. Gish, et al.
Published: (2011) -
Hepatocellular Carcinoma Clinical Research
Published: (2012) -
ANGIOGENESIS INHIBITORS FOR THE TREATMENT OF HEPATOCELLULAR CARCINOMA
by: Massimiliano Berretta, et al.
Published: (2016) -
Application of nanotechnology in the treatment of hepatocellular carcinoma
by: Liu Cai, et al.
Published: (2024) -
Invasive methods of hepatocellular carcinoma treatment
by: Gulziya Ismailova, et al.
Published: (2017)